probucol has been researched along with Ventricular Dysfunction, Left in 3 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined whether antioxidant and antiinflammatory treatment with probucol decreases myocardial oxidative stress and inflammation and attenuates the progression of left ventricular (LV) dysfunction and remodeling (dilatation) in tachycardia-induced HF." | 7.71 | Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. ( Egashira, K; Hayashidani, S; Machida, Y; Nakamura, R; Takeshita, A; Takeya, M; Tsutsui, H; Utsumi, H, 2002) |
| " We examined whether antioxidant and antiinflammatory treatment with probucol decreases myocardial oxidative stress and inflammation and attenuates the progression of left ventricular (LV) dysfunction and remodeling (dilatation) in tachycardia-induced HF." | 3.71 | Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. ( Egashira, K; Hayashidani, S; Machida, Y; Nakamura, R; Takeshita, A; Takeya, M; Tsutsui, H; Utsumi, H, 2002) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Pretreatment with probucol attenuates reperfusion-induced decreases in LVV in the heterotopic rat heart isograft model." | 1.30 | Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft. ( Jia, CX; Rabkin, DG; Spotnitz, HM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, R | 1 |
| Egashira, K | 1 |
| Machida, Y | 1 |
| Hayashidani, S | 1 |
| Takeya, M | 1 |
| Utsumi, H | 1 |
| Tsutsui, H | 1 |
| Takeshita, A | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Rabkin, DG | 1 |
| Jia, CX | 1 |
| Spotnitz, HM | 1 |
3 other studies available for probucol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated | 2002 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft.
Topics: Abdomen; Adenosine; Allopurinol; Animals; Antioxidants; Body Water; Cardiac Volume; Glutathione; Hea | 1999 |